Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 683 results

Media Release / Jul 01, 2011

Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease

Arcapta is the only once-daily long-acting beta2-agonist (LABA) approved in US for maintenance treatment of airflow obstruction in patients with COPDClinical studies with Arcapta showed sustained…
Media Release / Jul 01, 2011

Novartis receives FDA approval for Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
Media Release / May 25, 2011

Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid

Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate1,2Regulatory filings for the use of ACZ885 in…
Media Release / May 25, 2011

Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid
Media Release / May 24, 2011

Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour

New professional cycling team, called NOW and Novartis for MS, to compete nationally and ride tandem with MS patients in National MS Society’s bike rides Program kicks-off on the eve of World MS Day…
Media Release / May 24, 2011

Novartis teams up with Phil Keoghan, host of “The Amazing Race,” to raise awareness for multiple sclerosis through inspirational national bike tour
Media Release / May 07, 2011

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

- Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumors (NET) of pancreatic origin(1)- Afinitor represents a new approach to…
Media Release / May 06, 2011

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Media Release / Apr 11, 2011

Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows

Gilenya delayed the progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment11 scientific abstracts on Gilenya…
Media Release / Apr 11, 2011

Novartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows

‹ Previous page
1
…
59
60
61
62
63
64
65
…
69
› Next page